HK Stock Market Move | Hangzhou Tigermed Consulting (03347) fell more than 5% at the end of the day, with non-GAAP profit declining by more than 40%. Institutions say that the stock price has already reflected the positive factors.

Hangzhou Tigermed Consulting (03347) fell more than 5% in the afternoon session, down 4.85% as of the time of writing, closing at HK$51 with a trading volume of HK$1.3 billion. In terms of news, Hangzhou Tigermed Consulting recently announced that it expects to achieve a revenue of RMB 6.66-7.68 billion in 2025, a year-on-year increase of 1% to 16%; the net profit attributable to shareholders of the listed company is expected to be RMB 830 million to 1.23 billion, a year-on-year increase of 105% to 204%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be approximately RMB 330 million to 490 million, a year-on-year decrease of 61% to 43%. The current period's performance growth is mainly driven by investment income of financial assets and fair value changes, rather than the core business of clinical CRO. Lyon released a research report stating that Hangzhou Tigermed Consulting's order situation has improved, but the market is more concerned about the company's order conversion revenue efficiency and investment realization ability. Due to the fact that short-term positive factors have been reflected in the stock price, it is believed that the risks and returns are now balanced. The bank has lowered its earnings forecast for Hangzhou Tigermed Consulting for the 2027 fiscal year by 7% to reflect the increased uncertainties in long-term investment income.